A Phase 1, Randomized, Open-label, Parallel, Single-dose Study to Assess the Pharmacokinetics, Tolerability, and Absolute Bioavailability of Subcutaneous Administration of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Healthy Participants
Latest Information Update: 14 Oct 2025
At a glance
- Drugs BMS 986446 (Primary) ; BMS 986446 (Primary) ; Loratadine; Paracetamol
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 01 Oct 2025 Status changed from active, no longer recruiting to completed.
- 14 Aug 2025 Planned End Date changed from 4 Aug 2025 to 5 Sep 2025.
- 14 Aug 2025 Planned primary completion date changed from 4 Aug 2025 to 5 Sep 2025.